Trial Profile
Tolerability and Immunogenicity Study of FluvalAB Influenza Vaccine (trivalent, seasonal, active ingredient content: 15 microg HA/strain/0.5 mL) in Adults and Elderly Person
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jun 2011
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- 08 Jun 2011 New trial record